Strategies and challenges for the next generation of therapeutic antibodies

@article{Beck2010StrategiesAC,
  title={Strategies and challenges for the next generation of therapeutic antibodies},
  author={Alain Beck and Thierry Wurch and Christian Bailly and Nathalie Corvaia},
  journal={Nature Reviews Immunology},
  year={2010},
  volume={10},
  pages={345-352}
}
Antibodies and related products are the fastest growing class of therapeutic agents. By analysing the regulatory approvals of IgG-based biotherapeutic agents in the past 10 years, we can gain insights into the successful strategies used by pharmaceutical companies so far to bring innovative drugs to the market. Many challenges will have to be faced in the next decade to bring more efficient and affordable antibody-based drugs to the clinic. Here, we discuss strategies to select the best… Expand

Figures from this paper

Strategies for Development of Next Generation Antibody-Based Therapeutics
TLDR
Recent approaches employed for development of next generation antibody-based therapeutics are discussed, with the potential to displace their first-generation rivals based on improved therapeutic activity, safety, and increased dosing convenience. Expand
Developments and Challenges for mAb-Based Therapeutics
TLDR
The continuous increase in the number of approved monoclonal antibody (mAb)-based therapy suggests that mAbs, and their derivatives, will continue to be the focus of the biotherapeutics industry for years to come, but there are still challenges to be overcome. Expand
Coming-of-Age of Antibodies in Cancer Therapeutics.
TLDR
This review critically assess recent trends in the development and applications of bispecific antibodies, antibody-drug conjugates, and immune checkpoint inhibitors as cancer therapeutics and highlights recent US FDA approvals and clinical trials of antibody-based cancer therapies. Expand
Strategies and challenges for the next generation of antibody–drug conjugates
TLDR
Strategies to select the best target antigens as well as suitable cytotoxic drugs; the design of optimized linkers; the discovery of bioorthogonal conjugation chemistries; and toxicity issues are discussed. Expand
Next-generation optimized biotherapeutics - A review and preclinical study.
  • T. Ueda
  • Computer Science, Medicine
  • Biochimica et biophysica acta
  • 2014
TLDR
Since trials of protein engineering for biotherapeutics have been conducted, these preclinical approaches are also described and they are described as part of a Special Issue entitled: Recent advances in molecular engineering of antibody. Expand
Antibody therapy of cancer
TLDR
This Review outlines the fundamental strategies that are required to develop antibody therapies for cancer patients through iterative approaches to target and antibody selection, extending from preclinical studies to human trials. Expand
Therapeutic targets and recent advances in protein immunotoxins.
TLDR
This review summarizes the target moieties used in Immunotoxin constructs in different diseases and describes the recent advances in immunotoxin targeting. Expand
Mechanism of action of therapeutic monoclonal antibodies: promises and pitfalls of in vitro and in vivo assays.
TLDR
The major methods that are employed for testing the activity of therapeutic mAbs in vitro and in vivo in small animal models are reviewed and some of the pitfalls in these assays are pointed out. Expand
Antibodies and associates: Partners in targeted drug delivery
TLDR
An updated overview of the different aspects required for the successful development and engineering of antibody bioconjugates in current and emerging drug delivery technologies is presented. Expand
Clinical pharmacology of bispecific antibody constructs
TLDR
This knowledgebase on the clinical behavior of bispecific therapeutic proteins is poised to rapidly evolve over the next few years with many development programs having entered the clinical development stage. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 101 REFERENCES
Considerations for the development of therapeutic monoclonal antibodies.
TLDR
An increasing number of Investigational New Drug applications for therapeutic monoclonal antibodies (mAbs) have been submitted to US FDA over the past several years and recent findings highlight the need to more fully characterize these products and their activity. Expand
Optimization of Fc-mediated effector functions of monoclonal antibodies.
  • W. Strohl
  • Biology, Medicine
  • Current opinion in biotechnology
  • 2009
TLDR
There are at least 14 marketed and clinical candidate antibodies and Fc fusion proteins in which the Fc has been modified, either via changes in amino acid sequence or in glycoforms. Expand
Glycosylation as a strategy to improve antibody-based therapeutics
  • R. Jefferis
  • Biology, Medicine
  • Nature Reviews Drug Discovery
  • 2009
TLDR
Current knowledge of methods and avenues for their exploitation in the clinic are summarized, which allow the production of rMAbs bearing pre-selected oligosaccharides — glycoforms — to provide maximum efficacy for a given disease indication. Expand
Therapeutic antibodies for autoimmunity and inflammation
TLDR
How key insights obtained from the development of therapeutic antibodies complemented by newer antibody engineering technologies are delivering a second generation of therapeutic antibody with promise for greater clinical efficacy and safety is reviewed. Expand
Bispecific antibodies for cancer therapy: the light at the end of the tunnel?
TLDR
This review describes the most recent advances and clinical study results in the field of bispecific antibodies, a new class of molecules that might outshine conventional mAbs as cancer immunotherapeutics in a near future. Expand
Engineered protein scaffolds as next-generation antibody therapeutics.
TLDR
The technology shows a trend toward consolidation with a smaller set of systems that are being applied against multiple targets and in different settings, with emphasis on the development of drug candidates for therapy or in vivo diagnostics: Adnectins, Affibodies, Anticalins, DARPins, and engineered Kunitz-type inhibitors, among others. Expand
Discovery and development of biopharmaceuticals: current issues.
TLDR
As the field of therapeutic proteins continues to mature, the challenge of follow-on biologics needs to be addressed with the establishment of regulatory guidelines appropriate for the complexity of biotherapeutics. Expand
Antibodies to watch in 2010
TLDR
This overview of the 26 mAbs provides a brief description of the background and the on-going Phase 3 studies of each mAb, and will serve as a baseline against which future progress can be measured. Expand
Monoclonal antibodies: versatile platforms for cancer immunotherapy
TLDR
This work states that antibodies exhibit various immunomodulatory properties and, by directly activating or inhibiting molecules of the immune system, antibodies can promote the induction of antitumour immune responses and form the basis for new cancer treatment strategies. Expand
When binding is enough: nonactivating antibody formats.
TLDR
The state of the art for antibody-based therapeutics, designed to be nonactivating (i.e. do not engage the innate immune system's effector functions), is discussed, in both monovalent and bivalent formats. Expand
...
1
2
3
4
5
...